228 related articles for article (PubMed ID: 25009377)
1. Peroxisome proliferator-activated receptor α, a potential therapeutic target for alcoholic liver disease.
Nan YM; Wang RQ; Fu N
World J Gastroenterol; 2014 Jul; 20(25):8055-60. PubMed ID: 25009377
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
3. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
[TBL] [Abstract][Full Text] [Related]
4. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.
Lalloyer F; Wouters K; Baron M; Caron S; Vallez E; Vanhoutte J; Baugé E; Shiri-Sverdlov R; Hofker M; Staels B; Tailleux A
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1573-9. PubMed ID: 21474829
[TBL] [Abstract][Full Text] [Related]
6. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol induced steatohepatitis in mice.
Kong L; Ren W; Li W; Zhao S; Mi H; Wang R; Zhang Y; Wu W; Nan Y; Yu J
Lipids Health Dis; 2011 Dec; 10():246. PubMed ID: 22208561
[TBL] [Abstract][Full Text] [Related]
7. Hepatic non-parenchymal cells: Master regulators of alcoholic liver disease?
Seo W; Jeong WI
World J Gastroenterol; 2016 Jan; 22(4):1348-56. PubMed ID: 26819504
[TBL] [Abstract][Full Text] [Related]
8. Modulation of fatty acid and bile acid metabolism by peroxisome proliferator-activated receptor α protects against alcoholic liver disease.
Li HH; Tyburski JB; Wang YW; Strawn S; Moon BH; Kallakury BV; Gonzalez FJ; Fornace AJ
Alcohol Clin Exp Res; 2014 Jun; 38(6):1520-31. PubMed ID: 24773203
[TBL] [Abstract][Full Text] [Related]
9. Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress.
Okiyama W; Tanaka N; Nakajima T; Tanaka E; Kiyosawa K; Gonzalez FJ; Aoyama T
J Hepatol; 2009 Jun; 50(6):1236-46. PubMed ID: 19398233
[TBL] [Abstract][Full Text] [Related]
10. Polydatin alleviated alcoholic liver injury in zebrafish larvae through ameliorating lipid metabolism and oxidative stress.
Lai Y; Zhou C; Huang P; Dong Z; Mo C; Xie L; Lin H; Zhou Z; Deng G; Liu Y; Chen Y; Huang S; Wu Z; Sun X; Gao L; Lv Z
J Pharmacol Sci; 2018 Sep; 138(1):46-53. PubMed ID: 30245287
[TBL] [Abstract][Full Text] [Related]
11. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats.
Zhao X; Xue J; Wang XL; Zhang Y; Deng M; Xie ML
Int Immunopharmacol; 2014 Sep; 22(1):176-81. PubMed ID: 24993341
[TBL] [Abstract][Full Text] [Related]
12. HWL-088, a new and highly effective FFA1/PPARδ dual agonist, attenuates nonalcoholic steatohepatitis by regulating lipid metabolism, inflammation and fibrosis.
Hu L; Zhou Z; Deng L; Ren Q; Cai Z; Wang B; Li Z; Wang G
J Pharm Pharmacol; 2020 Nov; 72(11):1564-1573. PubMed ID: 32734608
[TBL] [Abstract][Full Text] [Related]
13. Demethyleneberberine, a natural mitochondria-targeted antioxidant, inhibits mitochondrial dysfunction, oxidative stress, and steatosis in alcoholic liver disease mouse model.
Zhang P; Qiang X; Zhang M; Ma D; Zhao Z; Zhou C; Liu X; Li R; Chen H; Zhang Y
J Pharmacol Exp Ther; 2015 Jan; 352(1):139-47. PubMed ID: 25362106
[TBL] [Abstract][Full Text] [Related]
14. Increased 4-hydroxynonenal protein adducts in male GSTA4-4/PPAR-α double knockout mice enhance injury during early stages of alcoholic liver disease.
Ronis MJ; Mercer KE; Gannon B; Engi B; Zimniak P; Shearn CT; Orlicky DJ; Albano E; Badger TM; Petersen DR
Am J Physiol Gastrointest Liver Physiol; 2015 Mar; 308(5):G403-15. PubMed ID: 25501545
[TBL] [Abstract][Full Text] [Related]
15. Potential relationship between hepatobiliary osteopontin and peroxisome proliferator-activated receptor alpha expression following ethanol-associated hepatic injury in vivo and in vitro.
Lee JH; Banerjee A; Ueno Y; Ramaiah SK
Toxicol Sci; 2008 Nov; 106(1):290-9. PubMed ID: 18703563
[TBL] [Abstract][Full Text] [Related]
16. Chrysanthemum morifolium attenuates metabolic and alcohol-associated liver disease via gut microbiota and PPARα/γ activation.
Liu D; Zhan J; Wang S; Chen L; Zhu Q; Nie R; Zhou X; Zheng W; Luo X; Wang B; Nie J; Ye X
Phytomedicine; 2024 Jul; 130():155774. PubMed ID: 38820659
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.
Pawlak M; Lefebvre P; Staels B
J Hepatol; 2015 Mar; 62(3):720-33. PubMed ID: 25450203
[TBL] [Abstract][Full Text] [Related]
18. NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease.
Li Y; Chen M; Zhou Y; Tang C; Zhang W; Zhong Y; Chen Y; Zhou H; Sheng L
Theranostics; 2020; 10(8):3579-3593. PubMed ID: 32206109
[No Abstract] [Full Text] [Related]
19. Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease.
Qiu LX; Chen T
World J Gastroenterol; 2015 Jan; 21(4):1099-107. PubMed ID: 25632182
[TBL] [Abstract][Full Text] [Related]
20. Targeting Peroxisome Proliferator-Activated Receptor-β/δ (PPARβ/δ) for the Treatment or Prevention of Alcoholic Liver Disease.
Koga T; Peters JM
Biol Pharm Bull; 2021; 44(11):1598-1606. PubMed ID: 34719638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
